Monte Rosa Therapeutics is searching for a toxicologist to direct nonclinical safety and toxicology work for programs to enable drug candidates during all phases from discovery through development.
This individual contributor role will contribute to the research and development strategy and will report to the Senior Director of Nonclinical Development, by designing, conducting or overseeing studies, analyzing and interpreting results, ensuring appropriate quality of documentation and record keeping, in close collaboration with other scientists, for a broad range of nonclinical activities:- in silico, in vitro, ex vivo, and in vivo studies;- non-GLP and GLP studies;- nonclinical pharmacology, PK/PD, and toxicology studies, mainly conducted at Contract Research Organizations (CROs).
The toxicologist will also support global regulatory activities related to nonclinical sections of filings including Investigational New Drugs (INDs), annual reports, Investor Brochures (IBs) and New Drug Applications (NDAs), and annual reports. The toxicologist will interact directly with multidisciplinary teams including biology, medicinal chemistry, CMC, DMPK, clinical science, in research and development projects, to move discovery candidates into development. Introduction and growth into regulatory toxicology will be an extension of this position. The ideal candidate will be able to help evolve Monte Rosa’s hit identification and hit-to-lead endeavors through embracing novel assay technologies, enhancing overall process and actively drive internal and external partnerships.

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.